Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest AstraZeneca Stories

2013-11-04 08:25:43

BEIJING, Nov. 4, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2013, after market closes on Tuesday, November 12, 2013 EST. The Company will host a conference call prior to the market opening on Wednesday, November 13, 2013, at 8:00 a.m. EST (November 13, 2013 at 9:00 p.m. China Standard Time) to review...

2013-11-01 08:28:02

Company chosen to be a MAIN/Stage presenter on November 6 CHAPEL HILL, N.C., Nov. 1, 2013 /PRNewswire/ -- G1 Therapeutics, Inc. today announced that it has been selected as a MAIN/Stage presenter at the 2013 Southeast BIO Investor & Partnering Forum to be held November 6-7 at the Jefferson Hotel in Richmond, Virginia. Christy Shaffer, Ph.D., Executive Chair of G1's Board of Directors, will present to the audience of potential investors and partners on the afternoon of November 6....

2013-10-31 08:32:34

BEIJING, Oct. 31, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is invited to participate in UBS Asia Healthcare CEO Summit held in Hong Kong on November 1, 2013. And Mr. Yin will join the panel discussion from 4:00 pm to 5:00 pm Beijing time, talking about Chinese healthcare industry and new product development strategy. About Sinovac...

2013-10-30 04:20:22

- Unrivalled early season broad spectrum insect control BASEL, Switzerland, Oct. 30, 2013 /PRNewswire/ -- Syngenta today announced the registration in Argentina of FORTENZA(TM), a novel seed treatment insecticide, for use on soybean, corn and sunflower. Further registrations are pending in multiple countries for both seed treatment and foliar uses across all major field crops. The global peak sales potential of the FORTENZA product family is expected to be around $300 million....

2013-10-29 11:52:10

Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature diagnosis, which can rapidly and comprehensively measure an individual’s vaccine response, promising to take much of the initial guesswork out of predicting effective vaccines. Professor Stephen Albert Johnston and Joseph Barten Legutki, used a mouse model of influenza infection to determine how...

2013-10-28 08:28:54

LA JOLLA, Calif., Oct. 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of an undisclosed oncology target by AstraZeneca under the strategic alliance to discover, develop, and commercialize microRNA therapeutics. Regulus and AstraZeneca continue to collaborate on three exclusive microRNA targets in cardiovascular and metabolic...

2013-10-28 08:28:19

WILMINGTON, Del., Oct. 28, 2013 /PRNewswire/ -- AstraZeneca today announced that the Arthritis Foundation has joined the Get Moving America campaign, a national initiative that encourages men and women to do daily simple movements to help reduce chronic stiffness and pain associated with osteoarthritis (OA). (Logo: http://photos.prnewswire.com/prnh/20130930/NY86955LOGO) The Get Moving America campaign, sponsored by AstraZeneca, was launched last month to establish a social media...

2013-10-24 23:19:12

Reportbuyer.com just published a new market research report: General Anxiety Disorder Global Clinical Trials Review, H2, 2013. London (PRWEB) October 24, 2013 General Anxiety Disorder Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “General Anxiety Disorder Global Clinical Trials Review, H2, 2013" provides data on the General Anxiety Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical...

2013-10-22 08:31:39

New Trial Triggers Milestone Payment to Array BOULDER, Colo., Oct. 22, 2013 /PRNewswire/ -- AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Array BioPharma (NASDAQ:...

China Reports New H7N9 Case, US Vaccine Trial May Have An Answer
2013-10-18 06:43:18

Lawrence LeBlond for redOrbit.com - Your Universe Online China’s National Health and Family Planning Center (NHFPC) has notified the World Health Organization (WHO) of a new laboratory-confirmed case of human infection with H7N9 avian influenza A. This is the first new case to be identified since August 11, 2013. The patient is a 35-year-old man from Zhejiang Province who was admitted to a hospital on October 8 and is in critical condition. The man, with the surname Liu, tested...